71.11
price up icon4.40%   3.00
pre-market  プレマーケット:  70.14   -0.97   -1.36%
loading
前日終値:
$68.11
開ける:
$69
24時間の取引高:
1.01M
Relative Volume:
0.92
時価総額:
$1.99B
収益:
$90.12M
当期純損益:
$-276.06M
株価収益率:
-48.71
EPS:
-1.46
ネットキャッシュフロー:
$-193.47M
1週間 パフォーマンス:
+1.05%
1か月 パフォーマンス:
+88.92%
6か月 パフォーマンス:
+97.64%
1年 パフォーマンス:
+8,327%
1日の値動き範囲:
Value
$68.00
$72.98
1週間の範囲:
Value
$64.50
$72.98
52週間の値動き範囲:
Value
$0.432
$75.67

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1106)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
61
Name
Twitter
@nektarnews
Name
次回の収益日
2025-03-12
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

Compare NKTR vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NKTR
Nektar Therapeutics
71.11 1.91B 90.12M -276.06M -193.47M -1.46
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.89 120.48B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
787.50 81.05B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
749.56 46.33B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.30 42.26B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.02 32.87B 5.36B 287.73M 924.18M 2.5229

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-10 アップグレード William Blair Mkt Perform → Outperform
2025-11-26 開始されました Citigroup Buy
2025-06-24 繰り返されました BTIG Research Buy
2025-06-24 繰り返されました H.C. Wainwright Buy
2025-04-11 アップグレード Jefferies Hold → Buy
2025-03-14 アップグレード Oppenheimer Perform → Outperform
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
Mar 04, 2026

Nektar Therapeutics at TD Cowen Conference: Immunology Focus - Investing.com Nigeria

Mar 04, 2026
pulisher
Mar 04, 2026

Nektar Therapeutics at TD Cowen Conference: Immunology Focus By Investing.com - Investing.com UK

Mar 04, 2026
pulisher
Mar 03, 2026

Nektar Therapeutics (HAM:ITH0) Selling and Marketing Expens - GuruFocus

Mar 03, 2026
pulisher
Mar 03, 2026

Assessing Nektar Therapeutics (NKTR) Valuation After New Multiple Sclerosis Collaboration With UCSF - Yahoo Finance

Mar 03, 2026
pulisher
Mar 03, 2026

Does Nektar (NKTR)–UCSF MS Collaboration Hint At A Broader Neuroscience Pivot For The Company? - Yahoo Finance

Mar 03, 2026
pulisher
Mar 03, 2026

Assessing Nektar Therapeutics (NKTR) Valuation After Recent Share Price Momentum And Undervaluation Narrative - simplywall.st

Mar 03, 2026
pulisher
Mar 02, 2026

BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $151 - 富途牛牛

Mar 02, 2026
pulisher
Mar 02, 2026

Erste Asset Management GmbH Takes $1 Million Position in Nektar Therapeutics $NKTR - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

Nektar Therapeutics (HAM:ITH0) Accounts Payable : €15.56 Mil (As of Sep. 2025) - GuruFocus

Mar 02, 2026
pulisher
Mar 02, 2026

Nektar Therapeutics (HAM:ITH0) Inventories, Work In Process : €0.00 Mil (As of Sep. 2025) - GuruFocus

Mar 02, 2026
pulisher
Mar 02, 2026

Nektar Therapeutics (HAM:ITH0) Short-Term Capital Lease Obl - GuruFocus

Mar 02, 2026
pulisher
Mar 02, 2026

Nektar Therapeutics (HAM:ITH0) Cash Flow from Others : €-60.04 Mil (TTM As of Sep. 2025) - GuruFocus

Mar 02, 2026
pulisher
Feb 28, 2026

Nektar Therapeutics (HAM:ITH0) Stock Price, Trades & News - GuruFocus

Feb 28, 2026
pulisher
Feb 28, 2026

Nektar Therapeutics to Participate in Two Investor Conferences in March - Sahm

Feb 28, 2026
pulisher
Feb 27, 2026

Nektar Therapeutics Stock Historical Valuations - GuruFocus

Feb 27, 2026
pulisher
Feb 27, 2026

Nektar Therapeutics (HAM:ITH0) Return-on-Tangible-Equity : -466.82% (As of Sep. 2025) - GuruFocus

Feb 27, 2026
pulisher
Feb 27, 2026

Nektar Therapeutics (HAM:ITH0) Cyclically Adjusted Book per Share : €0.00 (As of Sep. 2025) - GuruFocus

Feb 27, 2026
pulisher
Feb 27, 2026

Nektar Therapeutics (HAM:ITH0) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2025) - GuruFocus

Feb 27, 2026
pulisher
Feb 26, 2026

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets - Finviz

Feb 26, 2026
pulisher
Feb 26, 2026

United StatesGoodwin Advises Nektar Therapeutics On Its $460 Million Public Offering, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares - Mondaq

Feb 26, 2026
pulisher
Feb 26, 2026

Nektar Therapeutics sets March 12 call on 2025 financials - Stock Titan

Feb 26, 2026
pulisher
Feb 26, 2026

Nektar Therapeutics MS Collaboration Adds New Angle To Volatile Stock Story - simplywall.st

Feb 26, 2026
pulisher
Feb 25, 2026

Wall Street Analysts Think Nektar (NKTR) Could Surge 89.8%: Read This Before Placing a Bet - Finviz

Feb 25, 2026
pulisher
Feb 25, 2026

Nektar Therapeutics (NKTR) Price Target Increased by 13.48% to 132.45 - Nasdaq

Feb 25, 2026
pulisher
Feb 24, 2026

Nektar Therapeutics to Participate in Two Investor Conferences i - GuruFocus

Feb 24, 2026
pulisher
Feb 24, 2026

Wall Street experts predict that Nektar (NKTR) may climb by 89.8%: Consider this information before making an investment decision - Bitget

Feb 24, 2026
pulisher
Feb 24, 2026

Back-to-back investor conferences send Nektar to Boston and Miami - Stock Titan

Feb 24, 2026
pulisher
Feb 24, 2026

Nektar Therapeutics (NASDAQ:NKTR) Sets New 52-Week HighTime to Buy? - MarketBeat

Feb 24, 2026
pulisher
Feb 24, 2026

Nektar Therapeutics stock hits 52-week high at 75.19 USD By Investing.com - Investing.com India

Feb 24, 2026
pulisher
Feb 24, 2026

Nektar Therapeutics’ (NKTR) “Buy” Rating Reaffirmed at B. Riley Financial - Defense World

Feb 24, 2026
pulisher
Feb 23, 2026

A Look At Nektar Therapeutics (NKTR) Valuation After New UCSF Multiple Sclerosis Collaboration - simplywall.st

Feb 23, 2026
pulisher
Feb 23, 2026

Nektar Therapeutics (NKTR) Receives Positive Analyst Rating Upgr - GuruFocus

Feb 23, 2026
pulisher
Feb 23, 2026

B. Riley Securities Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $150 - 富途牛牛

Feb 23, 2026
pulisher
Feb 23, 2026

Nektar Therapeutics stock hits 52-week high at 75.19 USD - Investing.com

Feb 23, 2026
pulisher
Feb 23, 2026

B. Riley Raises Price Target on Nektar Therapeutics to $150 From $105, Keeps Buy Rating - marketscreener.com

Feb 23, 2026
pulisher
Feb 22, 2026

Rezpegaldesleukin Shows Sustained Benefit in Moderate-to-Severe Atopic Dermatitis in Phase 2 b trial - Medical Dialogues

Feb 22, 2026
pulisher
Feb 20, 2026

Jonathan Zalevsky Sells 180 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat

Feb 20, 2026
pulisher
Feb 20, 2026

Howard Robin Sells 423 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat

Feb 20, 2026
pulisher
Feb 20, 2026

What is Nektar Therapeutics’s valuation compared to sectorJuly 2025 Highlights & Weekly Stock Breakout Alerts - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

Persistent Asset Partners Ltd Takes $983,000 Position in Nektar Therapeutics $NKTR - MarketBeat

Feb 20, 2026
pulisher
Feb 19, 2026

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight - StreetInsider

Feb 19, 2026
pulisher
Feb 19, 2026

Nektar Therapeutics stock pops on $300M equity offering - MSN

Feb 19, 2026
pulisher
Feb 19, 2026

UCSF, Nektar team to test potential of antibody therapy for MS - Multiple Sclerosis News Today

Feb 19, 2026
pulisher
Feb 19, 2026

Which Is a Better Investment, Liquidia Corporation or Nektar Therapeutics Stock? - AAII.com

Feb 19, 2026
pulisher
Feb 19, 2026

Which Is a Better Investment, Amneal Pharmaceuticals, Inc. or Nektar Therapeutics Stock? - AAII

Feb 19, 2026
pulisher
Feb 18, 2026

Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy - Seeking Alpha

Feb 18, 2026
pulisher
Feb 18, 2026

Nektar Therapeutics and UCSF explore TNFR2 agonism in MS - BioWorld MedTech

Feb 18, 2026
pulisher
Feb 18, 2026

Nektar Therapeutics (NASDAQ:NKTR) Reaches New 12-Month HighShould You Buy? - MarketBeat

Feb 18, 2026
pulisher
Feb 18, 2026

45,042 Shares in Nektar Therapeutics $NKTR Bought by Readystate Asset Management LP - MarketBeat

Feb 18, 2026
pulisher
Feb 17, 2026

Nektar Therapeutics Announces Research Collaboration with University of California, San Francisco - marketscreener.com

Feb 17, 2026
pulisher
Feb 17, 2026

StockWatch: Nektar’s Rezpeg Sparks a Sweet “Comeback Story” - Genetic Engineering and Biotechnology News

Feb 17, 2026

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$47.43
price down icon 0.11%
$29.52
price up icon 6.00%
$57.80
price up icon 15.99%
$103.80
price up icon 3.02%
$149.88
price up icon 1.96%
biotechnology ONC
$299.02
price up icon 0.67%
大文字化:     |  ボリューム (24 時間):